AnDiCon Biotech

AnDiCon is a South Korean biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs). The company utilizes its proprietary AnDiCon (Antibody Directed Conjugation) platform, which employs a unique peptide-based linker for site-specific conjugation. This technology is designed to produce homogeneous ADCs with a controlled drug-to-antibody ratio (DAR), leading to improved pharmacokinetics and a wider therapeutic window compared to traditional random conjugation methods. AnDiCon is currently advancing an internal pipeline of ADC candidates focused on treating various solid tumors while actively seeking strategic partnerships to expand the application of its conjugation platform.